Mabylon AG, a Swiss clinical-stage biotechnology company focused on antibody-based therapies, has reported positive preliminary Phase 1a data for its lead candidate MY006 and announced the initiation of dosing in peanut-allergic patients under the Phase Ib portion of its ongoing first-in-human clinical study.

The company is developing human-derived, extended half-life antibodies designed to neutralise disease-relevant allergens and prevent allergic reactions. MY006, Mabylon’s lead programme, is being developed as a preventative treatment for peanut allergy, one of the most severe food allergies globally and a major area of unmet medical need.

The ongoing Phase 1a/2b study is a randomised, quadruple-blinded, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics (PK), immunogenicity and early clinical activity of MY006 in healthy volunteers as well as peanut-allergic adolescents and adults.

According to Mabylon, dosing in healthy volunteers under Part A of the study has been completed. Preliminary blinded data, collected through the end of April 2026, indicate that MY006 has shown a favourable safety profile to date, with no treatment-related serious adverse events or severe-intensity adverse reactions reported.

The company also stated that preliminary pharmacokinetic findings aligned closely with its internal modelling, demonstrating dose proportionality and an extended half-life, supporting continued clinical development. Based on the available safety and PK findings, the study’s Safety Monitoring Committee recommended progressing to Part B of the trial involving peanut-allergic individuals. Screening of patients for the next phase began in early May 2026.

The Phase 1b component will assess early clinical activity and explore desensitisation potential using placebo-controlled food challenge tests conducted at different intervals after MY006 administration.

Dr Niccolò Pengo, Chief Scientific Officer at Mabylon, said the transition into the patient study phase marks an important milestone for the company and reinforces confidence in MY006 as a differentiated preventive therapy for peanut allergy.

MY006 is designed as a subcutaneous multi-specific antibody therapy derived from patient antibodies and aims to provide long-term protection against allergic reactions, including potentially life-threatening anaphylaxis, through only a limited number of injections annually.

Alongside MY006, Mabylon also reported progress on its second development programme, MY010, targeting allergies linked to tree pollen species within the Fagales order, including birch, oak, hazel and alder pollen allergens. The programme has completed cell line development and entered Good Manufacturing Practice (GMP) manufacturing ahead of toxicology studies, regulatory filing preparations and future clinical trials.

The company is also establishing a Clinical Development Advisory Board for MY010, bringing together specialists in allergy and immunology to support programme advancement. Mabylon stated that additional funding secured beyond its CHF 30 million capital raise completed in 2025 will support the progression of both MY006 and MY010 through future development stages.

Dr. Alcide Barberis, Chief Executive Officer, Mabylon, said, “Mabylon aims to build a broad pipeline of antibody-based therapies for severe allergic diseases. The company’s multi-specific antibody platform is designed to simultaneously neutralise multiple allergens, potentially providing broader protection with fewer annual treatments.”

Mabylon is focused on harnessing naturally occurring human antibodies to develop therapies across allergy, inflammatory and neurodegenerative disease indications, with the company positioning its platform as an alternative to conventional antibody development approaches.